Literature DB >> 15014036

Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.

Dao M Nguyen1, William D Schrump, G Aaron Chen, Wilson Tsai, Phuongmai Nguyen, Jane B Trepel, David S Schrump.   

Abstract

PURPOSE: Recent insights regarding the pathogenesis of malignant pleural mesothelioma (MPM) provide new opportunities for targeted molecular therapies for this highly lethal disease. The present study was undertaken to examine the effects of the histone deacetylase inhibitor, Depsipeptide (DP) FK228, in conjunction with the cyclin-dependent kinase inhibitor, Flavopiridol (FLA), in cultured MPM cells. EXPERIMENTAL
DESIGN: Proliferation and apoptosis in drug-treated, virally transduced, or control cells were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and Apo-bromodeoxyuridine techniques. Western blot and ELISA techniques were used to examine signal transduction and cell cycle-related protein levels in MPM cells exposed to DP and/or FLA in the presence or absence of calphostin, phorbol-12,13-dibutyrate, 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole, or adenoviral p21 transduction.
RESULTS: DP (1-50 ng/ml x 6 h) or FLA (100-200 nM x 72 h) alone, mediated low-level, dose-dependent growth inhibition in MPM cells. In contrast, sequential DP/FLA treatment mediated marked growth inhibition and apoptosis in these cell lines. The cytotoxic effects of DP/FLA were considerably less pronounced in cultured normal cells. The proapoptotic effects of DP/FLA treatment coincided with inhibition of DP-mediated induction of p21 by FLA. Overexpression of p21 by adenoviral gene transfer techniques rendered MPM cells refractory to the cytotoxic effects of this treatment regimen. In p21 reporter assays, promoter activation by DP was antagonized by FLA. The magnitude of inhibition of DP-mediated p21 induction by FLA exceeded that observed with the pTEFb antagonist 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole. Calphostin C abrogated p21 induction mediated by DP and enhanced DP-mediated apoptosis in a manner comparable with FLA in MPM cells; in contrast, phorbol-12,13-dibutyrate blocked FLA-mediated inhibition of p21 induction by DP and markedly protected these cells from the apoptotic effects of sequential DP/FLA.
CONCLUSIONS: FLA abrogates DP-mediated induction of p21 expression, in part, via inhibition of protein kinase C signaling and markedly potentiates the cytotoxic effects of DP in MPM cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15014036     DOI: 10.1158/1078-0432.ccr-0901-3

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

Review 1.  Targeting the epigenome in malignant pleural mesothelioma.

Authors:  Kaitlin C McLoughlin; Andrew S Kaufman; David S Schrump
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.

Authors:  Susan E Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko; Robin Frye; Robert W Robey; Maria Turner; Erin R Gardner; William D Figg; Seth M Steinberg; Alex Ling; Tito Fojo; Kin Wah To; Richard L Piekarz
Journal:  Br J Haematol       Date:  2009-10-28       Impact factor: 6.998

3.  Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.

Authors:  Jen-Ming Huang; Michael A Sheard; Lingyun Ji; Richard Sposto; Nino Keshelava
Journal:  Mol Cancer Ther       Date:  2010-12       Impact factor: 6.261

4.  5-Amino-1-methyl-1H-benzimidazole.

Authors:  Jan Lokaj; Viktor Kettmann; Viktor Milata; Tomáš Solčan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-07-08

5.  Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21(WAF1/CIP1) dependent.

Authors:  Haiming Ding; Chunhua Han; Dongmei Guo; Dasheng Wang; Wenrui Duan; Ching-Shih Chen; Steven M D'Ambrosio
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

Review 6.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

7.  Epigenetic modifiers: basic understanding and clinical development.

Authors:  Richard L Piekarz; Susan E Bates
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

8.  Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.

Authors:  Mahadev Rao; Scott M Atay; Vivek Shukla; Young Hong; Trevor Upham; R Taylor Ripley; Julie A Hong; Mary Zhang; Emily Reardon; Patricia Fetsch; Markku Miettinen; Xinmin Li; Cody J Peer; Tristan Sissung; William D Figg; Assunta De Rienzo; Raphael Bueno; David S Schrump
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

9.  A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.

Authors:  Beata Holkova; Jeffrey G Supko; Matthew M Ames; Joel M Reid; Geoffrey I Shapiro; Edward Brent Perkins; Viswanathan Ramakrishnan; Mary Beth Tombes; Connie Honeycutt; Renee M McGovern; Maciej Kmieciak; Ellen Shrader; Martha D Wellons; Heidi Sankala; Austin Doyle; John Wright; John D Roberts; Steven Grant
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531

10.  The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status.

Authors:  Valentina Turinetto; Paola Porcedda; Luca Orlando; Mario De Marchi; Antonio Amoroso; Claudia Giachino
Journal:  BMC Cancer       Date:  2009-08-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.